A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis
Phase 3
Completed
- Conditions
- Lupus NephritisGlomerulonephritis, Membranous
- Registration Number
- NCT00404794
- Lead Sponsor
- Hospital Authority, Hong Kong
- Brief Summary
This is a prospective randomized open-label pilot study to compare mycophenolate mofetil in combination with corticosteroid treatment and tacrolimus in combination with corticosteroid treatment in membranous lupus nephritis. The change in urine protein excretion will be the primary outcome studied. The study duration will be 24 months for each patient.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- abnormal urine protein excretion and biopsy-proven membranous lupus nephritis
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Proteinuria
- Secondary Outcome Measures
Name Time Method Adverse effects
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of mycophenolate mofetil in treating membranous lupus nephritis?
How does tacrolimus compare to mycophenolate mofetil in managing glomerulonephritis in lupus patients?
Which biomarkers correlate with response to corticosteroid-based immunosuppressive therapies in lupus nephritis?
What are the adverse event profiles of mycophenolate mofetil and tacrolimus in combination with corticosteroids for lupus nephritis?
Are there alternative immunosuppressive combinations to mycophenolate mofetil and tacrolimus for membranous glomerulonephritis?
Trial Locations
- Locations (1)
Queen Mary Hospital
🇨🇳Hong Kong, China
Queen Mary Hospital🇨🇳Hong Kong, China